Cryo-Cell Intl Inc Up 4.45% To $3.99 After Earnings Beat

Cryo-Cell Intl Inc (CCEL) said after close Tuesday that it earned $0.1 per share in quarter four 2022.

On the revenue line, the company reported $7.8 million, beating estimates by $504 thousand.

In the same quarter a year ago, the company lost $0.08 per share on revenue of $7.3 million.

The stock is up 4.45% to $3.99 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Cryo-Cell Intl Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 0, putting Cryo-Cell Intl Inc in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $3.81 on February 15, 2023 and set a 52-week high on March 23, 2022 at $9.16.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. It is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.